Richard N Formica

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/694794/publications.pdf

Version: 2024-02-01

48 papers

1,488 citations

430874 18 h-index 330143 37 g-index

49 all docs 49 docs citations

49 times ranked

1993 citing authors

#	Article	IF	CITATIONS
1	Patient and Clinician Perceptions of Informed Consent and Decision Making About Accepting KDPl > 85 Kidneys. Transplantation Direct, 2022, 8, e1254.	1.6	7
2	Sustained Improvement in Patient Experience by Optimizing Patient Flow in Ambulatory Settings. Journal of Patient Experience, 2022, 9, 237437352210926.	0.9	1
3	The Role of Procurement Biopsies in Kidney Acceptance Decision Making and Kidney Discard: Perceptions of Physicians, Nurse Coordinators, and OPO Staff and Directors. Transplantation Direct, 2022, 8, e1299.	1.6	3
4	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation, 2022, 106, 2031-2043.	1.0	5
5	A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients' Five-Tier Rating System. Journal of the American Society of Nephrology: JASN, 2022, 33, 1613-1624.	6.1	3
6	Consensus conference on heart-kidney transplantation. American Journal of Transplantation, 2021, 21, 2459-2467.	4.7	49
7	Uncertainty in organ allocation is a catalyst for positive change. American Journal of Transplantation, 2021, 21, 1996-1997.	4.7	2
8	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLoS ONE, 2021, 16, e0247789.	2.5	11
9	Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act—a Chance to Celebrate and Reflect. Journal of the American Society of Nephrology: JASN, 2021, 32, 774-776.	6.1	13
10	Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 994-1004.	6.1	44
11	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	4.1	64
12	Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN's allocation policy. American Journal of Transplantation, 2021, 21, 3593-3607.	4.7	30
13	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 843-851.	1.0	8
14	Improving Transplant Program Performance Monitoring. Current Transplantation Reports, 2021, 8, 293-300.	2.0	3
15	It Is Time for Patient-Reported Outcome Measures to Be Included in the Approval Process for Solid Organ Transplant Medications. Journal of the American Society of Nephrology: JASN, 2021, 32, 2984-2986.	6.1	O
16	Should the United States employ free market practices to solve the hidden public health crisis of chronic kidney disease?. American Journal of Transplantation, 2020, 20, 1217-1218.	4.7	0
17	A call to action: Feasible strategies to reduce the discard of transplantable kidneys in the United States. Clinical Transplantation, 2020, 34, e13990.	1.6	8
18	Advancing American Kidney Healthâ€"New Opportunities for Collaborative Care. American Journal of Medicine, 2020, 133, e335-e337.	1.5	6

#	Article	IF	CITATIONS
19	Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal of the American Society of Nephrology: JASN, 2020, 31, 218-228.	6.1	13
20	The Broader Sharing of Deceased Donor Kidneys Is an Ethical and Legal Imperative. Journal of the American Society of Nephrology: JASN, 2020, 31, 1174-1176.	6.1	12
21	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45, 990-997.	5.4	127
22	Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 892-895.	4.5	23
23	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal of Transplantation, 2019, 19, 3035-3045.	4.7	44
24	ESKD Risk in Living Kidney Donors "Like Me― Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 970-971.	4.5	0
25	Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1778-1780.	6.1	1
26	Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards. Clinical Transplantation, 2019, 33, e13419.	1.6	61
27	Simultaneous Liver-Kidney Transplantation: Impact on Liver Transplant Patients and the Kidney Transplant Waiting List. Current Transplantation Reports, 2018, 5, 1-6.	2.0	38
28	The role of the kidney in combined liverâ€kidney transplantation. Liver Transplantation, 2018, 24, 164-165.	2.4	0
29	Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. Transplantation, 2018, 102, 673-680.	1.0	44
30	And equal access for all? The future of deceased donor kidney allocation. American Journal of Transplantation, 2018, 18, 1837-1838.	4.7	3
31	Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal of STD and AIDS, 2017, 28, 447-458.	1.1	21
32	Opportunities to Increase Availability of Deceased Donor Kidneys. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 871-873.	4.5	2
33	A critical assessment on kidney allocation systems. Transplantation Reviews, 2017, 31, 61-67.	2.9	23
34	Being Thoughtful about Desensitization. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1878-1880.	4.5	2
35	Perspectives on the Strengths and Weaknesses of the National Kidney Allocation System. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2056-2056.	4.5	9
36	Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modeling. PLoS ONE, 2017, 12, e0190277.	2.5	9

3

#	Article	IF	Citations
37	Simultaneous liver kidney transplantation. Current Opinion in Nephrology and Hypertension, 2016, 25, 577-582.	2.0	23
38	Changing the Kidney Allocation System: a 20-Year History. Current Transplantation Reports, 2016, 3, 39-44.	2.0	11
39	Allocating Deceased Donor Kidneys to Sensitized Candidates. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 377-378.	4.5	2
40	Opting out: confidentiality and availability of an â€̃alibi' for potential living kidney donors in the USA: TableÅ1. Journal of Medical Ethics, 2015, 41, 506-510.	1.8	17
41	Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2015, 26, 3114-3122.	6.1	172
42	New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. Journal of the American Society of Nephrology: JASN, 2014, 25, 1842-1848.	6.1	338
43	Cytomegalovirus Glomerulopathy and Cytomegalovirus Interstitial Nephritis on Sequential Transplant Kidney Biopsies. American Journal of Kidney Diseases, 2014, 63, 536-539.	1.9	18
44	The Kidney Allocation System. Surgical Clinics of North America, 2013, 93, 1395-1406.	1.5	131
45	A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. American Journal of Kidney Diseases, 2012, 60, 288-294.	1.9	24
46	When and how should immunosuppression be tapered for the failed renal allograft? Seminars in Dialysis, 2011, 24, 371-373.	1.3	0
47	Kidney Transplantation and HIV. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 924-928.	4.5	10
48	A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation, 2006, 21, 1389-1394.	0.7	53